Factors affecting the development of liver fibrosis in patients who experienced COVID-19

Author:

Kruchinina M. V.1ORCID,Pershina N. E.2,Svetlova I. O.1,Kruchinina E. V.3

Affiliation:

1. Research Institute of Internal and Preventive Medicine – branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences; Novosibirsk State Medical University

2. Research Institute of Internal and Preventive Medicine – branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences

3. Novosibirsk State Medical University

Abstract

The aim of the review is to highlight the main factors affecting the development of liver fibrosis and possible mechanisms of liver damage in patients who have experienced COVID-19. A search was carried out using keywords in the Scopus, Web of Science, and PubMed databases in literary sources of the last three years on factors associated with fibrogenesis in novel coronavirus infection.The review presents the main mechanisms of liver damage in COVID-19: direct effects on hepatocytes and cholangiocytes, hypoxia, and immune-mediated and drug-induced damage. We analyzed the significance of factors affecting fibrosis development in patients with COVID-19: chronic diffuse liver diseases, against which COVID-19 occurs, such as non-alcoholic fatty liver disease, alcohol-associated liver disease, chronic hepatitis B, C, and cirrhosis of the liver.Damage to the liver in coronavirus infection develops by several mechanisms. The development of COVID-19 against the background of diffuse liver pathology of various genesis is associated with progression of these diseases (increased fibrogenesis) and a poorer prognosis.

Publisher

Siberian State Medical University

Subject

Molecular Medicine

Reference51 articles.

1. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19). Vremennye metodicheskie rekomendatsii. Versiya 15 (22.02.2022). M.: Ministerstvo zdravookhraneniya Rossiiskoi Federatsii, 2022. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/VMR_COVID-19_V15.pdf (data obrashcheniya: 10.06.2022).

2. Driggers K.E., Sadowski B.W., Shagla E., Kwok R.M. Care of the hepatology patient in the COVID 19 era. Current Hepatology Reports. 2022;21(2):9–20. DOI: 10.1007/s11901-021-00581-x.

3. Nikiforov V.V., Suranova T.G., Mironov A.Yu., Zabozlaev F.G. Novaya koronavirusnaya infektsiya (COVID-19): etiologiya, epidemiologiya, klinika, diagnostika, lechenie i profilaktika. M., 2020:48.

4. Holmes K.V., Enjuanes L. The SARS coronavirus: a postgenomic era. Science. 2003;300(5624):1377–1378. DOI: 10.1126/science.1086418.

5. Mnatsakanyan M.G., Pogromov A.P., Lishuta A.S., Fomin V.V., Tashchyan O.V., Kuprina I.V. i dr. Mekhanizmy povrezhdeniya pecheni pri COVID-19. Terapevticheskii arkhiv. 2021;93(4):427–430. DOI: 10.26442/00403660.2021.04.2007 33.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3